Abstract:As SARS-CoV-2 continues to evolve and COVID-19 cases rapidly increase among children and adults, there is an urgent need for a safe and effective vaccine that can elicit systemic and mucosal humoral immunity to limit the emergence of new variants. Using the Chinese Hu191 measles virus (MeV-hu191) vaccine strain as a backbone, we developed MeV chimeras stably expressing the prefusion forms of either membrane-anchored, full-length spike (rMeV-preFS), or its soluble secreted spike trimers with the help of the SP-D trimerization tag (rMeV-S+SPD) of SARS-CoV-2 Omicron BA.2. The two vaccine candidates were administrated in golden Syrian hamsters through the intranasal or subcutaneous routes to determine the optimal immunization route for challenge. The intranasal delivery of rMeV-S+SPD induced a more robust mucosal IgA antibody response than the subcutaneous route. The mucosal IgA antibody induced by rMeV-preFS through the intranasal routine was slightly higher than the subcutaneous route, but there was no significant difference. The rMeV-preFS vaccine stimulated higher mucosal IgA than the rMeV-S+SPD vaccine through intranasal or subcutaneous administration. In hamsters, intranasal administration of the rMeV-preFS vaccine elicited high levels of NAbs, protecting against the SARS-CoV-2 Omicron BA.2 variant challenge by reducing virus loads and diminishing pathological changes in vaccinated animals. Encouragingly, sera collected from the rMeV-preFS group consistently showed robust and significantly high neutralizing titers against the latest variant XBB.1.16. These data suggest that rMeV-preFS is a highly promising COVID-19 candidate vaccine that has great potential to be developed into bivalent vaccines (MeV/SARS-CoV-2).

What problem does this paper attempt to address?

### Problems the paper attempts to solve This paper aims to develop a vaccine based on the measles virus (MeV) vector that can express the membrane - anchored full - length spike protein (preFS) of the SARS - CoV - 2 Omicron BA.2 variant or its soluble secreted trimeric spike protein (S + SPD) to induce effective systemic and mucosal humoral immune responses. Specifically, the researchers hope to address some of the limitations of current COVID - 19 vaccines through the following aspects: 1. **Improve immune durability**: The protection effect of current SARS - CoV - 2 vaccines begins to decline within 3 months after vaccination, and a third or fourth booster shot is required to enhance the neutralizing antibody levels. The researchers hope to develop a vaccine that can provide longer - term protection. 2. **Enhance cross - protection against new variants**: The cross - protection effect of existing vaccines against newly emerging SARS - CoV - 2 variants (such as Omicron BA.2) is limited. The researchers hope to improve the neutralizing ability of the vaccine against new variants by expressing the pre - fused form of the spike protein. 3. **Induce mucosal immunity**: Many symptoms of SARS - CoV - 2 infection are mainly manifested as respiratory symptoms, so inducing mucosal immunity is crucial for preventing virus transmission. The researchers vaccinated via both intranasal and subcutaneous routes and evaluated the impact of different routes on mucosal immunity. 4. **Safety and effectiveness**: The measles virus vaccine has been widely used in infants and young children since the 1960s and is considered one of the safe and effective vaccines. The researchers use the measles virus as a vector and hope to develop a safe and effective SARS - CoV - 2 vaccine. ### Overview of research methods 1. **Vaccine construction**: The researchers used the Chinese Hu191 measles virus vaccine strain as a backbone to construct two recombinant measles viruses (rMeV - preFS and rMeV - S + SPD), which respectively express the pre - fused form of the full - length spike protein and the soluble secreted trimeric spike protein. 2. **Animal experiments**: In the golden Syrian hamster model, vaccines were inoculated via both intranasal and subcutaneous routes to evaluate the immunogenicity and protective effects of the vaccines. 3. **Immune response detection**: Specific IgG and IgA antibodies were detected by ELISA, neutralizing antibody titers were detected by micro - neutralization assay, viral RNA load was detected by qRT - PCR, and lung lesions were analyzed by histopathology and immunohistochemistry. ### Main findings 1. **Immunogenicity**: Intranasal inoculation of rMeV - S + SPD induced a stronger mucosal IgA antibody response, while rMeV - preFS could induce relatively high mucosal IgA antibody levels whether inoculated via the intranasal or subcutaneous route. 2. **Protective effect**: Intranasal inoculation of the rMeV - preFS vaccine could significantly reduce the viral load of the Omicron BA.2 variant and reduce pathological changes. 3. **Neutralizing antibody**: The sera in the rMeV - preFS group showed strong neutralizing activity against the latest variant XBB.1.16. These data indicate that rMeV - preFS is a very promising COVID - 19 candidate vaccine and has great potential for development into a bivalent vaccine (MeV/SARS - CoV - 2).

Measles Virus-Based Vaccine Expressing Membrane-Anchored Spike of SARS-CoV-2 Inducing Efficacious Systemic and Mucosal Humoral Immunity in Hamsters

Next-generation intranasal Covid-19 vaccine: a polymersome-based protein subunit formulation that provides robust protection against multiple variants of concern and early reduction in viral load of the upper airway in the golden Syrian hamster model

Immunogenicity of Mucosal COVID-19 Vaccine Candidates Based on the Highly Attenuated Vesicular Stomatitis Virus Vector (VSVMT) in Golden Syrian Hamster

Immunogenicity of mucosal COVID-19 vaccine candidates based on the highly attenuated vesicular stomatitis virus vector (VSV MT ) in golden syrian hamster

Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera

A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease

Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity

Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective

Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters

Sterilizing Immunity Against SARS-CoV-2 in Hamsters Conferred by a Novel Recombinant Subunit Vaccine

A highly efficacious live attenuated mumps virus–based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike

Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters

A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model

CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge

A Single Intranasal or Intramuscular Immunization with Chimpanzee Adenovirus Vectored SARS-CoV-2 Vaccine Protects Against Pneumonia in Hamsters.

Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization

A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19

Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses

Intranasal or airborne transmission-mediated delivery of an attenuated SARS-CoV-2 protects Syrian hamsters against new variants

SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters

Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein